NOT KNOWN FACTS ABOUT PRIMOBOLAN

There were documented serious circumstances of peliosis hepatis, at times affiliated with liver failure and intra-abdominal hemorrhage; liver tumors, sometimes lethal; and blood lipid adjustments connected to elevated risk of atherosclerosis led FDA to get rid of approval in June 2023. Additional warnings involve the pitfalls connected to cholestat